Tag Archives: NIAID

Randomized Trials Key to Determining Effectiveness of Ebola Therapies and Vaccines

US researchers and regulators continue to support the use of randomized clinical trials to test potential treatments and vaccines to combat the Ebola virus, despite objections that this approach is unethical and unfair to vulnerable populations. Anthony Fauci, director of the National Institute of Allergy & Infectious Diseases (NIAID), articulated the case for “gold-standard” randomized […]
Posted in healthcare, R&D, Regulatory | Also tagged , , , | Leave a comment

Challenges in the March Toward an AIDS-Free Generation

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
Posted in Biotech, Events, FDA, healthcare, Market Access, Patient Communication, patient compliance, patient education, pricing, Regulatory, Safety | Also tagged , , , , , , | Leave a comment

Industry Optimism for Advancing TB Research

Scientists optimistic new combination regimens will improve TB treatment and reduce drug resistance, writes Jill Wechsler, Pharm Exec‘s Washington Editor. In honor of World TB Day March 24, research organizations and international health agencies announced important advances in the development of new therapies for stemming the spread of increasingly lethal tuberculosis strains. Each year, nearly […]
Posted in FDA, Global, healthcare, Op-Ed | Also tagged , , | Leave a comment
  • Categories

  • Meta